Mineralys' lorundrostat meets blood pressure endpoint in Phase 2 kidney disease trial
MLYS•Mineralys Therapeutics said its 59-participant Phase 2 Explore-CKD trial met its primary endpoint, with lorundrostat significantly reducing blood pressure and urinary protein loss versus placebo in patients with uncontrolled hypertension and chronic kidney disease.
1. Trial results
Mineralys Therapeutics published Phase 2 Explore-CKD results for lorundrostat in Kidney International. The 59-participant trial met its primary endpoint, showing significant blood pressure reductions versus placebo in patients with uncontrolled hypertension and chronic kidney disease. Lorundrostat also significantly reduced urinary protein loss, and adverse events were consistent with prior trials.
2. Next results
Longer-term results from Explore-CKD participants enrolled in the Transform-HTN extension study are expected shortly.
